Key terms
About BIIB
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest BIIB news
Yesterday
6:29am ET
QQQ ETF Update, 4/15/2024
Apr 12
6:56am ET
Biogen price target lowered to $260 from $280 at BofA
Apr 12
5:34am ET
SPY ETF Update, 4/12/2024
Apr 11
6:01am ET
Biogen price target lowered to $240 from $270 at JPMorgan
Apr 09
6:30am ET
Analysts Are Bullish on Top Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Recursion Pharmaceuticals (RXRX)
Apr 09
6:11am ET
QQQ ETF Update, 4/9/2024
Apr 04
2:36am ET
SPY ETF Update, 4/4/2024
Apr 03
5:39pm ET
Biogen price target lowered to $215 from $230 at Barclays
Apr 03
6:45am ET
QQQ ETF Update, 4/3/2024
Apr 01
9:45am ET
Buy Rating on Biogen: Focused on Leqembi’s IV Dosing Amidst SQ Formulation Delay
Apr 01
8:10am ET
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT) and Biogen (BIIB)
Apr 01
7:40am ET
QQQ ETF Update, 4/1/2024
Apr 01
5:33am ET
Biogen delayed Leqembi submission brings questions, says Barclays
Apr 01
5:26am ET
Hold Rating on Biogen Amidst Leqembi’s Regulatory Challenges and Competitive Pressures
Mar 31
7:48pm ET
Eisai, Biogen announce sBLA submission for monthly LEQEMBI IV maintenance dosing
Mar 29
4:58am ET
SPY ETF Update, 3/29/2024
Mar 28
6:11am ET
QQQ ETF Update, 3/28/2024
Mar 25
8:25am ET
Truist Financial Reaffirms Their Buy Rating on Biogen (BIIB)
Mar 22
9:23am ET
Eisai says CHMP oral explanation for lecanemab rescheduled
Mar 20
6:49am ET
QQQ ETF Update, 3/20/2024
Mar 19
8:40am ET
Analysts Offer Insights on Healthcare Companies: Crinetics Pharmaceuticals (CRNX) and Biogen (BIIB)
Mar 13
7:19am ET
Voyager Therapeutics appoints Toby Ferguson as CMO
Mar 13
2:11am ET
Analysts Are Bullish on Top Healthcare Stocks: Biogen (BIIB), Merck & Company (MRK)
Mar 11
9:14am ET
AbCellera gets upfront payment for collaboration with Biogen for antibodies
Mar 11
8:01am ET
Analysts Offer Insights on Healthcare Companies: Onconova Therapeutics (ONTX) and Biogen (BIIB)
Mar 08
9:55am ET
Early notable gainers among liquid option names on March 8th
Mar 06
7:37am ET
Biogen announces interim 6-month data from RESPOND study
Mar 05
11:15pm ET
RBC Capital Keeps Their Buy Rating on Biogen (BIIB)
Feb 27
7:27am ET
RBC Capital Reaffirms Their Buy Rating on Biogen (BIIB)
Feb 23
7:08am ET
Biogen’s QALSODY received positive opinion from CHMP
Feb 22
6:52am ET
Biogen price target lowered to $277 from $355 at Mizuho
No recent news articles are available for BIIB
No recent press releases are available for BIIB
BIIB Financials
Key terms
Ad Feedback
BIIB Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
BIIB Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
